More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage ...
Zacks Investment Research on MSN21h
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority TagApellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...
A minimum of 3 years of sustained clinical remission may protect against an increase in disease activity and the development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback